Growth patterns in the first three years of life in children with classical congenital adrenal hyperplasia diagnosed by newborn screening and treated with low doses of hydrocortisone

Hormone Research in Paediatrics

Volumn 75, Issue 1, 2011, Pages 32-37

  Bonfig, W ^a,b   Schmidt, H ^a   Schwarz, H P ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Congenital adrenal hyperplasia; Glucocorticoids; Growth; Newborn screening

Indexed keywords

FLUDROCORTISONE; HYDROCORTISONE;

ARTICLE; BIRTH; BODY HEIGHT; BODY SURFACE; BONE AGE; CHILD; CHILD GROWTH; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED STUDY; FEMALE; GENETICS; GROWTH RATE; HUMAN; HYPERANDROGENISM; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN SCREENING; PRESCHOOL CHILD; PRIORITY JOURNAL; SEX DIFFERENCE;

ADRENAL HYPERPLASIA, CONGENITAL; AGE DETERMINATION BY SKELETON; BODY HEIGHT; CHILD DEVELOPMENT; CHILD, PRESCHOOL; COHORT STUDIES; DRUG MONITORING; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; FEMALE; FLUDROCORTISONE; GENOTYPE; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROCORTISONE; INFANT; INFANT, NEWBORN; MALE; NEONATAL SCREENING;

EID: 79151472970     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000316973     Document Type: Article

References (20)

1. Speiser PW, White PC: Congenital adrenal hyperplasia. N Engl J Med 2003; 349: 776-788.
2. Hughes IA: Congenital adrenal hyperplasia - a continuum of disorders. Lancet 1998; 352: 752-754.
3. Cutler GB, Laue L: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 1990; 323: 1806-1813.
4. Laue L, Merke DP, Jones JV, Barnes KM, Hill S, Cutler GB: A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab 1996; 81: 3535-3539.
5. Einaudi S, Lala R, Corrias A, Matarazzo P, Pagliardini S, de Sanctis C: Auxological and biochemical parameters in assessing treatment of infants and toddlers with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Pediatr Endocrinol 1993; 6: 173-178.
6. Claahsen-van der Grinten HL, Noordam K, Borm GF, Otten BJ: Absence of increased height velocity in the first year of life in untreated children with simple virilizing congenital adrenal hyperplasia. J Clin Endocrinol Metab 2006; 91: 1205-1209.
7. Prader A, Largo RH, Molinari L, Issler C: Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development. Helv Paediatr Acta 1989; 52: 1-125.
8. Cole TJ, Freeman JV, Preece MA: Body mass index reference curves for the UK. Arch Dis Child 1995; 73: 25-29.
9. Greulich WW, Pyle SI: Radiographic Atlas of Skeletal Development of the Hand and Wrist, ed 2. Palo Alto, Stanford University Press, 1959.
10. Joint LWPES/ESPE CAH Working Group: Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Pediatric Endocrinology. J Clin Endocrinol Metab 2002; 87: 4048-4053.
11. Thilén A, Woods KA, Perry LA, Savage MO, Wedell A, Ritzén M: Early growth is not increased in untreated moderately severe 21-hydroxylase deficiency. Acta Paediatr 1995; 84: 894-898.
12. Balsamo A, Wasniewska M, Di Pasquale G, Salzano G, Baronio F, Bombaci S, De Luca F: Birth length and weight in congenital adrenal hyperplasia according to the different phenotypes. Eur J Pediatr 2006; 165: 380-383.
13. Jääskeläinen J, Voutilainen R: Growth of patients with 21-hydroxylase deficiency: an analysis of the factors influencing adult height. Pediatr Res 1997; 41: 30-33.
14. de Zegher F, Francois I, Boehmer ALM, Saggese G, Müller J, Hiort O, Sultan C, Clayton P, Brauner R, Cacciari E, Ibanez L, van Vliet G, Tiulpakov A, Saka N, Ritzen M, Sippell WG, Androgens and Fetal Growth Study Group: Androgens and fetal growth. Horm Res 1998; 50: 243-244.
15. Hofbauer LC, Khosla S: Androgen effects on bone metabolism: recent progress and controversies. Eur J Endocrinol 1999; 140: 271-286.
16. Hofbauer LC, Hicok KC, Khosla S: Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line. J Cellular Biochem 1998; 71: 96-108.
17. Gori F, Hofbauer LC, Conover CA, Khosla S: Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. Endocrinol 1999; 140: 5579-5586. (Pubitemid 30645345)
18. Hargitai G, Solyom J, Battelino T, Lebl J, Pribilincova Z, Hauspie R, Kovacs J, Waldhauser F, Frisch H, MEWPE-CAH Study Group: Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Horm Res 2001; 55: 161-171.
19. Manoli I, Kanaka-Gantenbein C, Voutetakis A, Maniati-Christidi M, Dacou-Voutetakis C: Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome. Clin Endocrinol 2002; 57: 669-676.
20. Stikkelbroeck NMML, vant Hof-Grootenboer BAE, Hermus ARMM, Otten BJ, vant Hof MA: Growth inhibition by glucocorticoid treatment in salt-wasting 21-hydroxylase deficiency: in early infancy and (pre)puberty. J Clin Endocrinol Metab 2003; 88: 3525-3530.